Carbetocin (Duratocin/Pabal)

Benefits

About Carbetocin (Duratocin/Pabal)

Carbetocin is an octapeptide synthetic analog of oxytocin with a longer duration of action, designed specifically for the prevention of uterine atony and postpartum hemorrhage (PPH). Structurally, it differs from native oxytocin through a deamination of the cysteine residue at position 1 and replacement of the disulfide bridge with a thioether linkage, rendering it resistant to enzymatic degradation by aminopeptidases and disulfidases. This modification extends its biological half-life approximately 4-10 fold compared to oxytocin while preserving full agonist activity at myometrial oxytocin receptors. At the molecular level, carbetocin is a functionally selective Gq agonist at the oxytocin receptor (OXTR), selectively activating the Gq/phospholipase C signaling cascade that drives myometrial contraction without significant activity at vasopressin V1a or V1b receptors. Uniquely, carbetocin induces beta-arrestin-independent internalization of the OXTR, and once internalized, the receptor does not recycle back to the plasma membrane — a feature that may contribute to its sustained uterotonic effect. The uterotonic response begins within 2 minutes of intravenous administration, with sustained rhythmic contractions observable for approximately 60 minutes, compared to only 10-15 minutes with equimolar oxytocin. The WHO-led CHAMPION trial (2018), the largest clinical trial ever conducted on PPH prevention, enrolled nearly 30,000 women across 23 sites in 10 countries and demonstrated that heat-stable carbetocin (100 mcg IM) was non-inferior to oxytocin (10 IU IM) for preventing blood loss of 500 mL or greater after vaginal birth. This pivotal trial led WHO to update its PPH prevention guidelines in 2018 and add heat-stable carbetocin to the Model List of Essential Medicines in 2019. Carbetocin offers logistical advantages over oxytocin in resource-limited settings because its heat-stable formulation does not require cold-chain storage, maintaining efficacy at temperatures up to 30 degrees Celsius for 3 years. Multiple randomized controlled trials in cesarean delivery settings have shown carbetocin reduces the need for additional uterotonic agents by 30-50% compared to standard oxytocin protocols. Carbetocin is currently approved in over 40 countries including EU member states (as Pabal), Canada (as Duratocin), Australia, Singapore, and multiple countries in Latin America, Asia, and Africa. It has not received FDA approval in the United States and remains classified as a research compound in the US market.

Who Should Consider Carbetocin (Duratocin/Pabal)

• Postpartum women after cesarean section
• Postpartum women after vaginal delivery
• Women at risk of uterine atony
• Obstetric patients in low-resource settings without cold-chain infrastructure
• Women with contraindications to ergometrine (hypertension, pre-eclampsia)

How Carbetocin (Duratocin/Pabal) Works

Carbetocin exerts its uterotonic effects primarily through selective agonism at the oxytocin receptor (OXTR), a G protein-coupled receptor densely expressed on myometrial smooth muscle cells, particularly during late pregnancy and the immediate postpartum period. Upon binding, carbetocin preferentially activates the Gq/11 signaling pathway with partial efficacy, triggering phospholipase C-beta (PLC-beta) activation, hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). IP3 stimulates calcium release from the sarcoplasmic reticulum, while DAG activates protein kinase C (PKC), both converging to drive actin-myosin cross-bridge cycling and sustained myometrial contraction. Unlike native oxytocin, carbetocin displays notable functional selectivity: it does not significantly activate vasopressin V1a or V1b receptors, which may explain its slightly more favorable cardiovascular side-effect profile. At the receptor trafficking level, carbetocin induces efficient OXTR internalization through a beta-arrestin-independent mechanism. Critically, once internalized, the OXTR does not recycle back to the plasma membrane as it does after oxytocin stimulation. This irreversible internalization pattern likely contributes to carbetocin's prolonged uterotonic activity, as it creates sustained intracellular signaling from endosomal compartments while preventing receptor desensitization-resensitization cycling. The structural modifications — deamination at position 1 and a thioether bridge replacing the native disulfide bond — confer resistance to enzymatic degradation by oxytocinase (placental leucyl/cystinyl aminopeptidase) and other serum peptidases, extending the plasma half-life 4-10 fold relative to oxytocin. The contractile response also involves prostaglandin synthesis: OXTR activation upregulates cyclooxygenase-2 (COX-2) and increases local prostaglandin F2-alpha production, which provides an additional myometrial contractile stimulus independent of the direct calcium-mediated pathway.

What to Expect

Dosing Protocol

Note: Carbetocin (trade names Duratocin, Pabal) is a long-acting synthetic oxytocin analog approved in the EU, Canada, Australia, and many other countries for the prevention of postpartum hemorrhage following cesarean section or vaginal delivery. It is NOT FDA-approved in the United States. A heat-stable formulation was added to the WHO Model List of Essential Medicines in 2019 following the landmark CHAMPION trial, making it particularly important for low-resource settings where cold-chain storage of oxytocin is unreliable. Carbetocin is administered as a single 100 mcg dose — no repeat dosing is required due to its prolonged duration of action (~60 minutes of uterotonic activity). It is intended exclusively for postpartum use and must only be administered after delivery of the infant.

How to Inject Carbetocin (Duratocin/Pabal)

Carbetocin is supplied as a ready-to-use 100 mcg/mL solution in single-dose vials or ampoules. For cesarean section: administer 100 mcg (1 mL) by slow intravenous injection over 1 minute, given as soon as possible after delivery of the infant, preferably before placental delivery. For vaginal delivery: administer 100 mcg (1 mL) by intramuscular injection or slow intravenous injection over 1 minute, immediately after delivery of the infant. Do not administer before delivery of the infant. Do not mix with other medications in the same syringe. Do not administer by rapid IV bolus, as this may cause transient hypotension and tachycardia. Only a single dose should be given — no additional carbetocin doses are recommended. The vial is for single use only; discard any unused portion. Administration should occur in a well-equipped obstetric unit with qualified staff and hemodynamic monitoring available.

Cycling Protocol

Pharmacokinetics

Side Effects

Carbetocin is generally well tolerated when used as directed for postpartum hemorrhage prevention. Very common side effects (>10%) include anemia (related to the delivery context). Common side effects (1-10%) include headache, tremor, nausea, vomiting, abdominal pain, flushing, feeling of warmth, tachycardia, bradycardia, hypotension, and metallic taste. Uncommon to rare side effects include dizziness, chest pain or tightness, dyspnea, pruritus, and back pain. Carbetocin has antidiuretic properties similar to oxytocin, and prolonged use or excessive fluid intake can theoretically lead to water intoxication and hyponatremia, though this is mitigated by the single-dose protocol. Cardiovascular effects are generally transient and mild, with some studies showing a more favorable hemodynamic profile than oxytocin (no sustained decrease in left ventricular ejection time). Allergic or hypersensitivity reactions are rare but have been reported.

Contraindications

Drug Interactions

Storage & Stability

Molecular Profile

Related Peptides

Oxytocin

Sexual Health

Vasopressin (Vasostrict)

Metabolic

Desmopressin (DDAVP)

Metabolic

Atosiban (Tractocile)

Sexual Health

References

1. Heat-Stable Carbetocin versus Oxytocin to Prevent Hemorrhage after Vaginal Birth (CHAMPION Trial)Clinical Trial
2. Double-blind comparison of carbetocin versus oxytocin in prevention of uterine atony after cesarean sectionClinical Trial
3. Carbetocin compared to oxytocin in emergency cesarean section: a randomized trialClinical Trial
4. Carbetocin is a Functional Selective Gq Agonist That Does Not Promote Oxytocin Receptor Recycling After Inducing Beta-Arrestin-Independent InternalisationPubMed 26751410
5. Carbetocin for the Prevention of Post-Partum Hemorrhage: A Review of Clinical Effectiveness, Cost-Effectiveness, and GuidelinesReview
6. Pabal (Carbetocin) 100 micrograms/mL Solution for Injection — Summary of Product Characteristics (UK EMC)FDA Label
7. DURATOCIN (Carbetocin) Product Monograph — Health CanadaFDA Label
8. Heat stable carbetocin or oxytocin for prevention of postpartum hemorrhage among women at risk: A secondary analysis of the CHAMPION trialPubMed 37357606